I have been one of the pioneers in bench-to-bedside translation of MDM2 inhibitors, the entirely novel class of cancer therapeutics. My papers have been frequently cited, leading to further work by many researchers. I first reported the therapeutic potential of MDM2 inhibitors in hematologic malignancies in 2005, and identified expression levels of MDM2 as biomarker for response in acute myeloid leukemia. The paper has been cited in ＞ 350 research papers, mainly in the field of cancer therapeutics, suggesting a critical impact on translational research in oncology. My papers on MDM2 inhibition and p53 have been cited over 1,000 times in other publications. We conducted Phase I study of the first-in-class MDM2 inhibitor RG7112. The study has established the safety, tolerability and proof-of-concept (Clin Cancer Res, 2016). I have more than 30 years’ experience both in research and clinical medicine, with over 130 peer-reviewed publications. I am specialized in clinical hematology and oncology with experience in clinical stem cell transplantation as a primary physician.